Description What is TIRZ? TIRZ is a synthetic peptide that activates two receptors simultaneously — the GLP-1 receptor and the GIP receptor — making it what researchers call a “dual incretin agonist.” Both of these receptors play important roles in how the body regulates appetite, processes blood sugar, and manages fat storage. While single-agonist compounds like Semaglutide target only GLP-1, TIRZ adds GIP receptor activation into the mix. Research suggests this dual mechanism produces enhanced effects on weight management and metabolic health compared to GLP-1-only approaches — which is why TIRZ has attracted enormous research interest and generated some of the most significant clinical trial data in the metabolic space. What Researchers Are Exploring Weight Loss Research TIRZ has produced some of the most impressive weight loss data in clinical research history. The SURMOUNT clinical trial programme demonstrated substantial body weight reductions in study participants — results that exceeded those seen with single-agonist compounds and drew significant attention from the scientific community. Blood Sugar & Diabetes Research Through its dual action on GLP-1 and GIP receptors, TIRZ has shown powerful effects on blood sugar regulation and insulin sensitivity. The SURPASS clinical trial programme explored its effects in the context of type 2 diabetes research, with results that were widely described as groundbreaking. Appetite Regulation Research suggests TIRZ significantly reduces appetite and food intake through its combined incretin receptor activity. The dual pathway approach appears to produce a more comprehensive effect on hunger and satiety signalling than targeting either receptor alone. Body Composition Research Beyond overall weight loss, studies have explored TIRZ’s effects on body composition — specifically whether the weight lost is predominantly fat rather than lean muscle. Research in this area has shown favourable results for fat-specific reduction. Worth Noting TIRZ has one of the strongest clinical trial programmes of any metabolic compound, with both the SURPASS and SURMOUNT trial series generating landmark data. Its dual mechanism — hitting both GLP-1 and GIP pathways — provides a genuinely different approach from single-agonist compounds and positions it as one of the most important compounds in modern metabolic research. For research use only. Not intended for human consumption. Not approved by the FDA or TGA.
